{
    "id": "2puoodrorrlnt7ui4sxw2k5ugkdntt5q",
    "title": "Masitinib as an add-on therapy to riluzole is beneficial in the treatment of amyotrophic lateral sclerosis (ALS) with acceptable tolerability: Results from a randomized controlled phase 3 trial",
    "info": {
        "author": [
            "Olivier Hermine, Faculty of Medicine, Paris Descartes University",
            "Luis Barbeito, Institut Pasteur de Montevideo",
            "Jes\u00fas S. Mora, Hospital Carlos III"
        ],
        "published": "July 21, 2017",
        "recorded": "May 2017",
        "category": [
            "Top->Medicine",
            "Top->Medicine->Neuroscience"
        ]
    },
    "url": "http://videolectures.net/encals2017_barbeito_mora_hermine_therapy/",
    "segmentation": [
        [
            "So I will talk about a new compound which is massive Geneva and show us the role of this compound in eyeless."
        ],
        [
            "So message in Ibiza.",
            "And we will do this this presentation by three people.",
            "Myself, I'm a co-founder of a science and working on kinase inhibitors in hematology.",
            "Actually and with barbecue with the director of the Neurodegeneration Laboratory in Pastor Institute in Montevideo and introduce more will present the clinical data of the studio."
        ],
        [
            "So why we use a message in EB in Ireland?"
        ],
        [
            "So first, a science is a French biotechnology and the goal of this biotechnology is to this affair the role of mast cells in various disease.",
            "So we know now that Masters is well known for this whole in energy.",
            "But there is more and more evidence is showing that must sesma pro critical role in inflammation in autoimmune disease.",
            "And now we have evidence that will improve always.",
            "Also in no generative disease.",
            "So mast cells are.",
            "Some kind of cells which orchestrate sometimes the inflammation in values pathology pathology features an masses matter act with macrophages and macroglossia, and we know that this says enter play together in the inflammatory process and to orchestrate this.",
            "Inflammation and activation of sets.",
            "A lot of kinases are play a critical look, for example to seek it 1000 kindness, which is a receptor which activate mast cells and also may and use their immigration and or on macrophages.",
            "We know that MCF self receptor may also and use a different session and activation of different type of model, site and macrophages and downstream these two receptors are also some kindness from the suckiness familiar trading Lynn Fest, San and film.",
            "So in the brain for example, it has been shown that in some kind of we call motor neuron units there is of some other place, sometimes some disease between mass sets and macro Leah, and the motor neurone.",
            "And actually in I guess it has been shown that by doing a PET scan and arises that in some instances microglia is activated in this disease."
        ],
        [
            "So to try to block this inflammation, what we do in ABC's with design some kinase inhibitor with the aim is to block the ATP binding pocket here and to prevent the phosphorylation or downstream substrates.",
            "And we design a very potent and highly efficient.",
            "He talked to block.",
            "Mankind is involved in inflammatory process including other show you before circuit for myself, an Abscess have receptor for macrophages.",
            "Macroglossia and Ilene for downstream signaling of this supplementary process.",
            "And by blocking these kinases when they block the proliferation, the survival, the differentiation, integration of mast cells, and macrophage and macroglossia inflammatory process.",
            "So now I will try to show I will show you an.",
            "Louis will show you all this kindness in return.",
            "May work in the preclinical model of Alice.",
            "Thanks Lester noon thanks to Terry, that time foundation for this invitation to share with you the accounts."
        ],
        [
            "So I will briefly show the mechanism of action of Macedonia.",
            "We have been working in in this drug during the last five years an an all started when we found a population of glial cells with aberrant features in the spinal cord that heavily proliferate around motor neurons.",
            "This was published in this PNS paper in 2011.",
            "This cells that we call.",
            "ABBA sales Abra national site emerge after the symptomatic phase of the disease and rapidly expand, and they are extremely neurotoxic for motor neurons in culture.",
            "So when we went to, we started to find a chemotherapy to stop the proliferation of ABBA cells in LS in the using the rat model.",
            "So at that time we found that massive nip and this was a suggestion by Olivier mean that my city need and in general tier synchronizing hitters could target these cells by targeting the CCF one receptor which is specific for the macrophage and microglial image.",
            "And then we started to to treat rat with mascitti nip orally and we found that it completely prevented the appearance of ourselves and also.",
            "Importantly, decrease the micro liosis in during the symptomatic phase of the disease.",
            "Most important, we start the treatment.",
            "Or frat.",
            "After paralysis answered so resembling the clinical setting of illness, and when we did this, we observed a delay of about two weeks in the in the survival of rats as you see here.",
            "And this effect was still maintained when the treatment started.",
            "Seven days after paralysis onset.",
            "And this is the main data and this was recently published in Journal of Rare Inflammation."
        ],
        [
            "Of course, when we went to see the motor neuron survival, we observed from the periphery to the spinal cord, it very important protection.",
            "At the level of the neuromuscular junction innervation, as you see here by synaptophysin, and never Filomena staining contacting the the postsynaptic plates and you see here how masetti need completely revert during 2 weeks, the loss of innovative neuromuscular junctions also in the sciatic nerve there is here you see the damage of the sciatic nerve measured by neurofilament.",
            "And how is is prevented by massive need treatment and also the level of motor neurone there?",
            "Is it protection both at the level of numbers and size of neurons?"
        ],
        [
            "The second mechanism of action of machine it could be in the periphery are these are unpublished data and I will present them tomorrow, but we observed that in prefer there is a predominance of muscles that.",
            "Extremely in high number infiltrates the intermission in the musical.",
            "This this this study was done in the extensor muscle, so there is a huge huge infiltration by myself.",
            "These muscles as you see here interact with the generated motor nerve endings in green muscles and you see how they seems to be attracted by the motor nerve endings and all.",
            "This is pretty much prevented by mascitti need treatment during 2 weeks so.",
            "This could be a second mechanism of action of my city.",
            "Need that explain, at least in the rat, the protective effect in a window of two or three weeks after paralysis answered."
        ],
        [
            "So tomorrow we will present much more about this preclinical studies.",
            "If you want to wake up early, there will be a session at 8:00 o'clock and I will present in detail all these preclinical studies.",
            "But in conclusion, Masita nips in the rat model appeared to to be unique among other airless available drugs because it is effective when treatment is started after paralysis onset and it exists.",
            "Narrow protection but a multi target activity involving microglia, macrophages and mast cells both in the central nervous system and in the periphery.",
            "Thank you.",
            "I live such as more now.",
            "With afternoon"
        ],
        [
            "Thank you very much to the foundation to every letter and for this invitation.",
            "I'm pleased to present you the results of a pivotal study.",
            "Randomized double blind, single control.",
            "Parallel groups faced three trials to assess the efficacy and safety of massive.",
            "You need less patience.",
            "Final result.",
            "Hawaii come back.",
            "The final results at the title, so I don't know if I have to talk more.",
            "I should elaborate on this.",
            "Is supposed to be here.",
            "Will ever even that."
        ],
        [
            "This study rationale we have just heard their message and if a fire synchronizing hitter that are acting on the CSF one receptors and that has demonstrated to reduce the post paralysis in a prosperous red model, the progression of their paralysis.",
            "And so I will know elaborate on that.",
            "I will go directly to the study results."
        ],
        [
            "Is going too fast?",
            "OK, I'll present you the study design basis characteristic, that is position of this line.",
            "The results of this study that it will include safety and final soon."
        ],
        [
            "We study had three arms randomized, one to one to 11 Macedonia, 4.5 milligrams per kilogram of a second arm.",
            "3 milligrams per kilogram per day.",
            "And placebo all in real soul on an oral dose twice a day's the trial treatment.",
            "The trials treatment lasted for 48 weeks.",
            "Safety assessment include the usual lab and clinical evaluations.",
            "There was an independent data safety monitoring committee that reviewed the data.",
            "6 monthly.",
            "The primary variable was the absolute change in the revised LS Functional Rating scale score at 48 weeks.",
            "Secondary variables.",
            "Where the forced vital capacity they combine assessment of functional survival that was used in the previous desperately pixel trial.",
            "The quality of life scale, the Alsac 40.",
            "Overall survival and PFS or progression free survival.",
            "This is a time to event and point in which the event is death or a predefined deterioration.",
            "In this case, we used nine points of iteration be in the LS functional rating score.",
            "This is a key secondary endpoint that was added for financial analysis.",
            "After discussion with the European Medicine Agency, 394 patients were recruited in nine countries in 32 sites.",
            "After the part in an approval of the IRP's Local and national on December 2016, the last recruited pacing completed 48 weeks of treatment."
        ],
        [
            "The inclusion exclusion criteria were quite similar to those in previous trials and quite representative of the General Ellis population.",
            "Main inclusion criteria included spiky unfamiliar Elise cases with Alaska Real criteria of Level Lab supported, clinically, probable, and definitely a less on a stable dose of loose all with up to 36 months of this is an for spider capacity of at least 60%.",
            "The main exclusion criteria, among others, where the presence of a gastrostomy, an any medical condition with specified criteria at my affect the safety of the patient, or the conduct of the trail of his results."
        ],
        [
            "A guy soon this trial was is there in Erica Eynon trials the randomization process.",
            "The following factors were used to minimize the bias between groups by relevance in their randomization algorithm.",
            "The rate of progression of the disease as measured by the functional scale, deterioration in points loss per month.",
            "Since this is sunset was established first, we believe that many trials may have failed just because of no consideration of these significant.",
            "Terroristic factor or their stratification factors where.",
            "Use as usual, decider once if spinal versus bolvar the Afr's score at baseline and vietsub at baseline.",
            "We study included also the trail sites regions with Europe and Canada, Eastern Europe versus other countries, in this case Argentina."
        ],
        [
            "The.",
            "Pretrial probation rate was calculated using modify kamirez formula.",
            "It was calculated now from the diagnosis from the time of diagnosis, but from the time of of disease onset, the formula goes.",
            "BLS FRS score at date of 1st.",
            "Symptom of this is stab Lish had 48 minus the score at baseline divided by the time from first symptom to baseline.",
            "For symptom As for symptom of sign of diseases that is understood that any any it was understood as first symptom.",
            "Any progressive focal weakness or atrophy and that would include any slurring of a syllable or any or any clumsiness in hand and foot and excludes fasciculations and cramps.",
            "Detailed questioning of the patient and family established the month of unsaid, an even there was a clear date of onset, or if no was the first day of the month, so the score was 48.",
            "Two distinct courts, where differentiated at randomization, those with a rate of progression of less than 1.1 points per month that we call it normal progressors an sorry.",
            "An adult with a progression of equal or more than one point, one that we call it.",
            "Faster processors this cut off was prospectively declaring the protocol ensuring the validity validity of the study design and the primary analysis.",
            "In the final analysis sequence was made with the normal professors and the fast progressors, but the targeted population for primary analysis was the normal process cord cord that we assumed was going to be higher than 80% of the total trials population."
        ],
        [
            "The fact that this population is working.",
            "The fact that this publication had different prognosis is confirmed by the Kaplan Meier univariate analysis on survival probability of the entire trial population.",
            "Regardless of the treatment given, it shows the expected diversions on survival probability between those two groups."
        ],
        [
            "This study have an Alpha of .5 and a power of 80% to detect 3.3 points difference on the LS FRS score between placebo and one message in a group.",
            "381 patients were required throughout the 90, four were created in Interana, analysis was planned and done after 50% of the trials population reach the Week 48 with positive results.",
            "But I will not extend on that since we are talking about the final results."
        ],
        [
            "The efficacy analysis were conducted as per protocol in a stepwise manner following a fixed sequence method to control the global family wise error rate at a point of five level for the primary analysis of each dose.",
            "Secondary analysis.",
            "This is analysis on the secondary variables where perform if the primary analysis was significant at the point of five level step one analyze the chains in the LSF score for normal progressors almost in 4.5.",
            "Message normal process on placebo using the modified laptop situation, carryforward method and read randomization tests.",
            "If conclusive.",
            "At the .5 significance level, the analysis continued in Step 2.",
            "Step 2 analyze.",
            "The normal protesters on.",
            "Unless I'm missing.",
            "Normal progressors and on Macedonia 3.0.",
            "Batrus those on Placeables say using the same method.",
            "An step three and four analyze normal am faster processors altogether on my city 4.5 and massive 3.0 respectively, versus the placebo control."
        ],
        [
            "For the primary analysis, the missing values were replaced based on the modified loss observation carryforward method for the different versions of discontinuation.",
            "Following several sensitivity rules and Rule 1 main, one for the analysis as per protocol imputation was done in cases of discontinuation due to toxicity or lack of efficacy.",
            "No imputation was done in other cases since their northern observed values are considered missing at random.",
            "Hold 'em gates of Death via score was replaced by several two key sensitivity analysis were provided, incorporating all patients.",
            "The intention to treat population based on the imputation model for missing values."
        ],
        [
            "Let's see the patients characteristics and disposition at baseline."
        ],
        [
            "Baseline practices of the samples in a good pick up the general ILS population and the different treatment arms were balance 133 patients on placebo, 130 on messaging 4.5 one 131 on marketing, 3 point no.",
            "38% were women, 62% men and male female ratio of 1.684% were normal processors versus 16 fast progressors mean production rate was .7 per month in the intention to treat population .5 per month in the normal progressors BLS functional rating score at baseline was between 37.7 and 39.3 been slightly lower in the massive arms as it was.",
            "The first vital capacity.",
            "Main aids was around 55.5.",
            "Bulbar onset patients were 17% versus 80.",
            "Three of his spinal onsets, group groups within regions were also balance, being about 64% of the patients from Western Europe and North America.",
            "Five person from Eastern Europe, 31% from other countries, Argentina."
        ],
        [
            "The ADT population included 394 patients.",
            "Of those, 330 normal progressors safety assessment population included patients with at least one drug intake.",
            "The efficacy assessment population, including patients with at least one post baseline evaluation in three well balanced arms.",
            "On on all assessments, normal pressures remain about 84% of the total population."
        ],
        [
            "Cheap.",
            "Different courts remain well balanced till the end, as similar proportion of patients reached the Week 48 around 60% of the total population of normal and fast progressors 65% of the normal process court."
        ],
        [
            "The study results were as follow."
        ],
        [
            "As defined in the protocol, step one analyze the normal process scored almost in 4.5 versus the normal process score on placebo."
        ],
        [
            "Prespecified primary analysis of the trials.",
            "Main in point, the absolute change in the islets.",
            "FRS score at 48 weeks of the normal process.",
            "Court showed that normal producers taking 4.5 milligrams per kilo per day had a least square.",
            "Mean deterioration of nine point 4.",
            "Name name .24 points versus 12.63 those normal process on placebo.",
            "This represents a difference of three point 39 points with a significant value of .015."
        ],
        [
            "The primary analysis was supported by several key sensitivity analysis based on imputation model.",
            "On reasons for discontinuation all of these sensitivity analysis resulted, positive as at a significant P value."
        ],
        [
            "The last two of these analysis included the entire intention to treat population.",
            "Rule 6 is a single imputation method.",
            "Copy in increments from similar patients.",
            "Imputation is done by clustering of similar patience by side of onset by region and treatment group and then using the mean main increment within the group to impute for that value.",
            "Route 7 is same as Rule 6, but imputation includes a penalty of 50% to those patients who discontinued due to lack of efficacy.",
            "Both rules showed showed benefit at significant P values.",
            "She.",
            "Showed the same benefit at significant P values.",
            "This analysis followed the European Medicine Agency guidance."
        ],
        [
            "On a graph.",
            "Of the LS FRS slopes.",
            "We can appreciate different progressions rates of both courts.",
            "Normal patients on massive normal producers.",
            "Patients on Macedonia 4.5 deteriorated at the rate of .77 per month versus 1.5 those on placebo.",
            "Do.",
            "This is 27% reduction of the slope drop above the mostly accepted threshold of 20% of a clinically meaningful benefit."
        ],
        [
            "I said before the trial enrolled patients with the disease of up to 36 months.",
            "The poster analysis of the patients with the disease duration of up to 18 an up to 24 months at onset of treatment showed that the treatment effect increase inversely to the richest duration.",
            "Three points at three point, 39 points of means.",
            "Difference of Macedonia versus placebo in those with less than 36 months.",
            "That's deep.",
            "The trials population the complete trails population.",
            "Versus 3.8 points.",
            "If only analyze the patients with up to 20 four months of disease had answered of the triel versus 4.4 points difference.",
            "If we get patients with the disease up to 18 months at the onset of the trial.",
            "Most patients at the this is the difference.",
            "Absurdity why it's moving this.",
            "OK.",
            "This was a difference of a 27%.",
            "Of these two values, there is a difference of a 35% of the two values between placebo.",
            "An treated patients more space inside the diagnosis.",
            "When is when the therapy is initiated.",
            "They usually have less than 18 months of this is so we we should expect that this the sooner the patient is treated after they are gnosis, the more benefit is going to obtain from from the drug."
        ],
        [
            "The analysis.",
            "Of the secondary valuable, they BFS and points showed benefit also again, this time to have an endpoint was established as the time that the patient takes to reach 9 points drop in the LS functional rating scale or death.",
            "Normal producers on Macedonia 4.5 loss 9 points or die at the median of 20 months beds for 16 months.",
            "Those on placebo.",
            "With a Wilkinson P value of .0 fifteen.",
            "This represents a benefit of a 25% read."
        ],
        [
            "Action time.",
            "The analysis of these secondary variable that changes in the Alsac 40.",
            "The quality of life scale showed again a positive result at 48 weeks.",
            "The patients normal plus normal producers on Macedonia 4.5 deteriorated, 7.75 points less on the scale than those normal process on placebo.",
            "This represents a 28.5% improvement sustained by a significant significant P value of.",
            "In 08."
        ],
        [
            "The analysis of the first secondary endpoint, the change in the first vital capacity of 48 weeks, was also positive defensive means at 48 weeks of 7.5 points and improvement of 22% at the P value of .03."
        ],
        [
            "The analysis of a fourth secondary variable.",
            "They combine assessment of functional survival, show their numerical benefit, but did not reach significant level, and so was the analysis of their fifth secondary variable.",
            "Overall survival and medical benefit without significance, we know.",
            "The patients that to detect significant difference in overall survival, we need trials with longer duration and large larger sample sizes."
        ],
        [
            "As a stab Lish, Step 2 analyze the efficacy of the normal process core taking massive net 3.0 MG per."
        ],
        [
            "Killer one day.",
            "But the primary analysis, the change in the areas FL score.",
            "There was a numerical benefit of 273 points, but the P value of .06 was slightly above the significant level of .05 trend.",
            "This numerical benefit represents her retardation of the rate of progression of a 24% point.",
            "72 points per month versus .92 per month."
        ],
        [
            "With a P value of .05.",
            "The analysis of the Alsac 40 deterioration showed a statistically significant benefit for the normal professors.",
            "All machine 3.0 with the least square mean of 23.6 points.",
            "Those on placebo versus 15.6 those on messaging.",
            "If the quality of life score deteriorated, a significant 34% less."
        ],
        [
            "However, no significant benefit was observed in the analysis of the secondary endpoints progression free survival force, vital capacity caps, and overall survival."
        ],
        [
            "This sequence, preestablished step three, and step four, and allies B total population normal plus faster processors."
        ],
        [
            "No significant benefit was observed in the primary analysis.",
            "The changing the ILS FRS score of this court.",
            "Normal producers on massive need 4.5 or all massive need 3.0 no analysis on secondary variables were then done.",
            "However."
        ],
        [
            "In a post of analysis, normal fast progressors almost 84.5 with up to 20 four months of this is at entry, no up to 36 as it was in the entire trial.",
            "Just that group of patients had any statistically significant median progression.",
            "Free survival of 15 months versus 11 on Windows on placebo.",
            "This 36% improvement.",
            "Similar result was obtained in the normal and fast Progressors population or Macedonia 4.5 with up to 18 months of this is at entry.",
            "These results, as at as those in the previously described postdoc analysis or normal processors, support the impression that they Macedonia treatment seems to be more effective.",
            "The sooner is initiated."
        ],
        [
            "Safety profile"
        ],
        [
            "The adverse events profile of Massive was acceptable when compared to placebo.",
            "Although there is a difference in serious or severe adverse event numbers, the Chi Square P values were not significant at all categories.",
            "Adverse event leading to death included all adverse events with onset while treated or within 20 days of discontinuation that ended in death.",
            "None was related to the study treatment.",
            "Safety profile of Machine if Placerville Shalin system organ class deserves appears acceptable so where severe adverse events were spread across various system organs but in limited numbers here presented those with the frequency equal or higher than 2% in any arm.",
            "The treatment was in general well tolerated.",
            "Most common non serious adverse event where skin rashes that mostly resolved in few days spontaneously or by antihistaminic therapy.",
            "Discontinuing this study drug for a few days or reducing his dose.",
            "4.7% of patients on messaging is 4.5 had to permanently discontinue the treatment because of this one case of possible Patrick toxicity was reported that resolved after treatment discontinuation and a short lasting.",
            "Immunosuppressive therapy and two others.",
            "See."
        ],
        [
            "And two others with high elevation of ALT and AST and bilirubin were suspicious of and resolve without treatment after discontinuation.",
            "My significant operationally increase levels of Ald NST battery may also be a path to toxic, and their combination may contribute to that specific adverse event in genetically predisposed patients to be studied."
        ],
        [
            "On summary"
        ],
        [
            "Madden, if at the doors of 4.5 milligrams but below a day or night twice a day, oral administration demonstrated a significant therapeutic benefit in patients with the production rate on the LS FRS at baseline of less than 1.1 points per month.",
            "Those patients experiences lowering the functional decoration of a 27%.",
            "Delate this is progression of 25% quality of life at 28% higher and adelaid loss of respiratory function of a 22%.",
            "Safety susceptible by the Patrick function controls are recommended.",
            "The effects the effect of the massive seems to be dose dependent patients on Mass Effect 3.0 experience a benefit, but fell slightly short on significant in the functional deterioration, though will treats significance on quality of life.",
            "The benefit is not only dependent.",
            "On a dose of the city, but also in the time of the disease when the treatment is initiated, the shorter duration, the more effective the treatment.",
            "All patients normal and fast.",
            "Progressors or Macedonia 4.5 had a progression.",
            "Free survival 35% higher than those on placebo.",
            "When therapy was initiated less.",
            "Less than 40.",
            "But when did Washington state there the last less than 20 four months of this is?",
            "As they decide this of this trial seems to demonstrate.",
            "Much did, it provides a new and significant therapeutic option for around an 85% of the LS population, probably more so if the treatment is initiated early in the disease.",
            "It compared favorably with another recently approved therapy.",
            "Thank you very much for your attention."
        ]
    ],
    "summarization": {
        "clip_0": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "So I will talk about a new compound which is massive Geneva and show us the role of this compound in eyeless.",
                    "label": 0
                }
            ]
        },
        "clip_1": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "So message in Ibiza.",
                    "label": 0
                },
                {
                    "sent": "And we will do this this presentation by three people.",
                    "label": 0
                },
                {
                    "sent": "Myself, I'm a co-founder of a science and working on kinase inhibitors in hematology.",
                    "label": 0
                },
                {
                    "sent": "Actually and with barbecue with the director of the Neurodegeneration Laboratory in Pastor Institute in Montevideo and introduce more will present the clinical data of the studio.",
                    "label": 1
                }
            ]
        },
        "clip_2": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "So why we use a message in EB in Ireland?",
                    "label": 0
                }
            ]
        },
        "clip_3": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "So first, a science is a French biotechnology and the goal of this biotechnology is to this affair the role of mast cells in various disease.",
                    "label": 0
                },
                {
                    "sent": "So we know now that Masters is well known for this whole in energy.",
                    "label": 0
                },
                {
                    "sent": "But there is more and more evidence is showing that must sesma pro critical role in inflammation in autoimmune disease.",
                    "label": 0
                },
                {
                    "sent": "And now we have evidence that will improve always.",
                    "label": 0
                },
                {
                    "sent": "Also in no generative disease.",
                    "label": 0
                },
                {
                    "sent": "So mast cells are.",
                    "label": 0
                },
                {
                    "sent": "Some kind of cells which orchestrate sometimes the inflammation in values pathology pathology features an masses matter act with macrophages and macroglossia, and we know that this says enter play together in the inflammatory process and to orchestrate this.",
                    "label": 0
                },
                {
                    "sent": "Inflammation and activation of sets.",
                    "label": 0
                },
                {
                    "sent": "A lot of kinases are play a critical look, for example to seek it 1000 kindness, which is a receptor which activate mast cells and also may and use their immigration and or on macrophages.",
                    "label": 0
                },
                {
                    "sent": "We know that MCF self receptor may also and use a different session and activation of different type of model, site and macrophages and downstream these two receptors are also some kindness from the suckiness familiar trading Lynn Fest, San and film.",
                    "label": 0
                },
                {
                    "sent": "So in the brain for example, it has been shown that in some kind of we call motor neuron units there is of some other place, sometimes some disease between mass sets and macro Leah, and the motor neurone.",
                    "label": 0
                },
                {
                    "sent": "And actually in I guess it has been shown that by doing a PET scan and arises that in some instances microglia is activated in this disease.",
                    "label": 0
                }
            ]
        },
        "clip_4": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "So to try to block this inflammation, what we do in ABC's with design some kinase inhibitor with the aim is to block the ATP binding pocket here and to prevent the phosphorylation or downstream substrates.",
                    "label": 0
                },
                {
                    "sent": "And we design a very potent and highly efficient.",
                    "label": 0
                },
                {
                    "sent": "He talked to block.",
                    "label": 0
                },
                {
                    "sent": "Mankind is involved in inflammatory process including other show you before circuit for myself, an Abscess have receptor for macrophages.",
                    "label": 0
                },
                {
                    "sent": "Macroglossia and Ilene for downstream signaling of this supplementary process.",
                    "label": 0
                },
                {
                    "sent": "And by blocking these kinases when they block the proliferation, the survival, the differentiation, integration of mast cells, and macrophage and macroglossia inflammatory process.",
                    "label": 0
                },
                {
                    "sent": "So now I will try to show I will show you an.",
                    "label": 0
                },
                {
                    "sent": "Louis will show you all this kindness in return.",
                    "label": 0
                },
                {
                    "sent": "May work in the preclinical model of Alice.",
                    "label": 0
                },
                {
                    "sent": "Thanks Lester noon thanks to Terry, that time foundation for this invitation to share with you the accounts.",
                    "label": 0
                }
            ]
        },
        "clip_5": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "So I will briefly show the mechanism of action of Macedonia.",
                    "label": 0
                },
                {
                    "sent": "We have been working in in this drug during the last five years an an all started when we found a population of glial cells with aberrant features in the spinal cord that heavily proliferate around motor neurons.",
                    "label": 0
                },
                {
                    "sent": "This was published in this PNS paper in 2011.",
                    "label": 0
                },
                {
                    "sent": "This cells that we call.",
                    "label": 0
                },
                {
                    "sent": "ABBA sales Abra national site emerge after the symptomatic phase of the disease and rapidly expand, and they are extremely neurotoxic for motor neurons in culture.",
                    "label": 0
                },
                {
                    "sent": "So when we went to, we started to find a chemotherapy to stop the proliferation of ABBA cells in LS in the using the rat model.",
                    "label": 0
                },
                {
                    "sent": "So at that time we found that massive nip and this was a suggestion by Olivier mean that my city need and in general tier synchronizing hitters could target these cells by targeting the CCF one receptor which is specific for the macrophage and microglial image.",
                    "label": 0
                },
                {
                    "sent": "And then we started to to treat rat with mascitti nip orally and we found that it completely prevented the appearance of ourselves and also.",
                    "label": 0
                },
                {
                    "sent": "Importantly, decrease the micro liosis in during the symptomatic phase of the disease.",
                    "label": 0
                },
                {
                    "sent": "Most important, we start the treatment.",
                    "label": 0
                },
                {
                    "sent": "Or frat.",
                    "label": 0
                },
                {
                    "sent": "After paralysis answered so resembling the clinical setting of illness, and when we did this, we observed a delay of about two weeks in the in the survival of rats as you see here.",
                    "label": 0
                },
                {
                    "sent": "And this effect was still maintained when the treatment started.",
                    "label": 0
                },
                {
                    "sent": "Seven days after paralysis onset.",
                    "label": 0
                },
                {
                    "sent": "And this is the main data and this was recently published in Journal of Rare Inflammation.",
                    "label": 0
                }
            ]
        },
        "clip_6": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Of course, when we went to see the motor neuron survival, we observed from the periphery to the spinal cord, it very important protection.",
                    "label": 1
                },
                {
                    "sent": "At the level of the neuromuscular junction innervation, as you see here by synaptophysin, and never Filomena staining contacting the the postsynaptic plates and you see here how masetti need completely revert during 2 weeks, the loss of innovative neuromuscular junctions also in the sciatic nerve there is here you see the damage of the sciatic nerve measured by neurofilament.",
                    "label": 0
                },
                {
                    "sent": "And how is is prevented by massive need treatment and also the level of motor neurone there?",
                    "label": 0
                },
                {
                    "sent": "Is it protection both at the level of numbers and size of neurons?",
                    "label": 0
                }
            ]
        },
        "clip_7": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "The second mechanism of action of machine it could be in the periphery are these are unpublished data and I will present them tomorrow, but we observed that in prefer there is a predominance of muscles that.",
                    "label": 1
                },
                {
                    "sent": "Extremely in high number infiltrates the intermission in the musical.",
                    "label": 0
                },
                {
                    "sent": "This this this study was done in the extensor muscle, so there is a huge huge infiltration by myself.",
                    "label": 0
                },
                {
                    "sent": "These muscles as you see here interact with the generated motor nerve endings in green muscles and you see how they seems to be attracted by the motor nerve endings and all.",
                    "label": 0
                },
                {
                    "sent": "This is pretty much prevented by mascitti need treatment during 2 weeks so.",
                    "label": 0
                },
                {
                    "sent": "This could be a second mechanism of action of my city.",
                    "label": 0
                },
                {
                    "sent": "Need that explain, at least in the rat, the protective effect in a window of two or three weeks after paralysis answered.",
                    "label": 0
                }
            ]
        },
        "clip_8": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "So tomorrow we will present much more about this preclinical studies.",
                    "label": 0
                },
                {
                    "sent": "If you want to wake up early, there will be a session at 8:00 o'clock and I will present in detail all these preclinical studies.",
                    "label": 1
                },
                {
                    "sent": "But in conclusion, Masita nips in the rat model appeared to to be unique among other airless available drugs because it is effective when treatment is started after paralysis onset and it exists.",
                    "label": 1
                },
                {
                    "sent": "Narrow protection but a multi target activity involving microglia, macrophages and mast cells both in the central nervous system and in the periphery.",
                    "label": 1
                },
                {
                    "sent": "Thank you.",
                    "label": 0
                },
                {
                    "sent": "I live such as more now.",
                    "label": 0
                },
                {
                    "sent": "With afternoon",
                    "label": 0
                }
            ]
        },
        "clip_9": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "Thank you very much to the foundation to every letter and for this invitation.",
                    "label": 0
                },
                {
                    "sent": "I'm pleased to present you the results of a pivotal study.",
                    "label": 0
                },
                {
                    "sent": "Randomized double blind, single control.",
                    "label": 0
                },
                {
                    "sent": "Parallel groups faced three trials to assess the efficacy and safety of massive.",
                    "label": 0
                },
                {
                    "sent": "You need less patience.",
                    "label": 0
                },
                {
                    "sent": "Final result.",
                    "label": 0
                },
                {
                    "sent": "Hawaii come back.",
                    "label": 0
                },
                {
                    "sent": "The final results at the title, so I don't know if I have to talk more.",
                    "label": 0
                },
                {
                    "sent": "I should elaborate on this.",
                    "label": 0
                },
                {
                    "sent": "Is supposed to be here.",
                    "label": 0
                },
                {
                    "sent": "Will ever even that.",
                    "label": 0
                }
            ]
        },
        "clip_10": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "This study rationale we have just heard their message and if a fire synchronizing hitter that are acting on the CSF one receptors and that has demonstrated to reduce the post paralysis in a prosperous red model, the progression of their paralysis.",
                    "label": 0
                },
                {
                    "sent": "And so I will know elaborate on that.",
                    "label": 0
                },
                {
                    "sent": "I will go directly to the study results.",
                    "label": 0
                }
            ]
        },
        "clip_11": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Is going too fast?",
                    "label": 0
                },
                {
                    "sent": "OK, I'll present you the study design basis characteristic, that is position of this line.",
                    "label": 1
                },
                {
                    "sent": "The results of this study that it will include safety and final soon.",
                    "label": 0
                }
            ]
        },
        "clip_12": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "We study had three arms randomized, one to one to 11 Macedonia, 4.5 milligrams per kilogram of a second arm.",
                    "label": 0
                },
                {
                    "sent": "3 milligrams per kilogram per day.",
                    "label": 0
                },
                {
                    "sent": "And placebo all in real soul on an oral dose twice a day's the trial treatment.",
                    "label": 0
                },
                {
                    "sent": "The trials treatment lasted for 48 weeks.",
                    "label": 1
                },
                {
                    "sent": "Safety assessment include the usual lab and clinical evaluations.",
                    "label": 0
                },
                {
                    "sent": "There was an independent data safety monitoring committee that reviewed the data.",
                    "label": 0
                },
                {
                    "sent": "6 monthly.",
                    "label": 0
                },
                {
                    "sent": "The primary variable was the absolute change in the revised LS Functional Rating scale score at 48 weeks.",
                    "label": 1
                },
                {
                    "sent": "Secondary variables.",
                    "label": 0
                },
                {
                    "sent": "Where the forced vital capacity they combine assessment of functional survival that was used in the previous desperately pixel trial.",
                    "label": 0
                },
                {
                    "sent": "The quality of life scale, the Alsac 40.",
                    "label": 1
                },
                {
                    "sent": "Overall survival and PFS or progression free survival.",
                    "label": 0
                },
                {
                    "sent": "This is a time to event and point in which the event is death or a predefined deterioration.",
                    "label": 0
                },
                {
                    "sent": "In this case, we used nine points of iteration be in the LS functional rating score.",
                    "label": 0
                },
                {
                    "sent": "This is a key secondary endpoint that was added for financial analysis.",
                    "label": 0
                },
                {
                    "sent": "After discussion with the European Medicine Agency, 394 patients were recruited in nine countries in 32 sites.",
                    "label": 0
                },
                {
                    "sent": "After the part in an approval of the IRP's Local and national on December 2016, the last recruited pacing completed 48 weeks of treatment.",
                    "label": 0
                }
            ]
        },
        "clip_13": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "The inclusion exclusion criteria were quite similar to those in previous trials and quite representative of the General Ellis population.",
                    "label": 0
                },
                {
                    "sent": "Main inclusion criteria included spiky unfamiliar Elise cases with Alaska Real criteria of Level Lab supported, clinically, probable, and definitely a less on a stable dose of loose all with up to 36 months of this is an for spider capacity of at least 60%.",
                    "label": 1
                },
                {
                    "sent": "The main exclusion criteria, among others, where the presence of a gastrostomy, an any medical condition with specified criteria at my affect the safety of the patient, or the conduct of the trail of his results.",
                    "label": 0
                }
            ]
        },
        "clip_14": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "A guy soon this trial was is there in Erica Eynon trials the randomization process.",
                    "label": 0
                },
                {
                    "sent": "The following factors were used to minimize the bias between groups by relevance in their randomization algorithm.",
                    "label": 0
                },
                {
                    "sent": "The rate of progression of the disease as measured by the functional scale, deterioration in points loss per month.",
                    "label": 1
                },
                {
                    "sent": "Since this is sunset was established first, we believe that many trials may have failed just because of no consideration of these significant.",
                    "label": 1
                },
                {
                    "sent": "Terroristic factor or their stratification factors where.",
                    "label": 0
                },
                {
                    "sent": "Use as usual, decider once if spinal versus bolvar the Afr's score at baseline and vietsub at baseline.",
                    "label": 0
                },
                {
                    "sent": "We study included also the trail sites regions with Europe and Canada, Eastern Europe versus other countries, in this case Argentina.",
                    "label": 0
                }
            ]
        },
        "clip_15": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "The.",
                    "label": 0
                },
                {
                    "sent": "Pretrial probation rate was calculated using modify kamirez formula.",
                    "label": 0
                },
                {
                    "sent": "It was calculated now from the diagnosis from the time of diagnosis, but from the time of of disease onset, the formula goes.",
                    "label": 0
                },
                {
                    "sent": "BLS FRS score at date of 1st.",
                    "label": 1
                },
                {
                    "sent": "Symptom of this is stab Lish had 48 minus the score at baseline divided by the time from first symptom to baseline.",
                    "label": 1
                },
                {
                    "sent": "For symptom As for symptom of sign of diseases that is understood that any any it was understood as first symptom.",
                    "label": 0
                },
                {
                    "sent": "Any progressive focal weakness or atrophy and that would include any slurring of a syllable or any or any clumsiness in hand and foot and excludes fasciculations and cramps.",
                    "label": 1
                },
                {
                    "sent": "Detailed questioning of the patient and family established the month of unsaid, an even there was a clear date of onset, or if no was the first day of the month, so the score was 48.",
                    "label": 0
                },
                {
                    "sent": "Two distinct courts, where differentiated at randomization, those with a rate of progression of less than 1.1 points per month that we call it normal progressors an sorry.",
                    "label": 0
                },
                {
                    "sent": "An adult with a progression of equal or more than one point, one that we call it.",
                    "label": 0
                },
                {
                    "sent": "Faster processors this cut off was prospectively declaring the protocol ensuring the validity validity of the study design and the primary analysis.",
                    "label": 0
                },
                {
                    "sent": "In the final analysis sequence was made with the normal professors and the fast progressors, but the targeted population for primary analysis was the normal process cord cord that we assumed was going to be higher than 80% of the total trials population.",
                    "label": 1
                }
            ]
        },
        "clip_16": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "The fact that this population is working.",
                    "label": 0
                },
                {
                    "sent": "The fact that this publication had different prognosis is confirmed by the Kaplan Meier univariate analysis on survival probability of the entire trial population.",
                    "label": 0
                },
                {
                    "sent": "Regardless of the treatment given, it shows the expected diversions on survival probability between those two groups.",
                    "label": 1
                }
            ]
        },
        "clip_17": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "This study have an Alpha of .5 and a power of 80% to detect 3.3 points difference on the LS FRS score between placebo and one message in a group.",
                    "label": 1
                },
                {
                    "sent": "381 patients were required throughout the 90, four were created in Interana, analysis was planned and done after 50% of the trials population reach the Week 48 with positive results.",
                    "label": 1
                },
                {
                    "sent": "But I will not extend on that since we are talking about the final results.",
                    "label": 0
                }
            ]
        },
        "clip_18": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "The efficacy analysis were conducted as per protocol in a stepwise manner following a fixed sequence method to control the global family wise error rate at a point of five level for the primary analysis of each dose.",
                    "label": 1
                },
                {
                    "sent": "Secondary analysis.",
                    "label": 0
                },
                {
                    "sent": "This is analysis on the secondary variables where perform if the primary analysis was significant at the point of five level step one analyze the chains in the LSF score for normal progressors almost in 4.5.",
                    "label": 0
                },
                {
                    "sent": "Message normal process on placebo using the modified laptop situation, carryforward method and read randomization tests.",
                    "label": 0
                },
                {
                    "sent": "If conclusive.",
                    "label": 1
                },
                {
                    "sent": "At the .5 significance level, the analysis continued in Step 2.",
                    "label": 0
                },
                {
                    "sent": "Step 2 analyze.",
                    "label": 0
                },
                {
                    "sent": "The normal protesters on.",
                    "label": 0
                },
                {
                    "sent": "Unless I'm missing.",
                    "label": 0
                },
                {
                    "sent": "Normal progressors and on Macedonia 3.0.",
                    "label": 0
                },
                {
                    "sent": "Batrus those on Placeables say using the same method.",
                    "label": 0
                },
                {
                    "sent": "An step three and four analyze normal am faster processors altogether on my city 4.5 and massive 3.0 respectively, versus the placebo control.",
                    "label": 0
                }
            ]
        },
        "clip_19": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "For the primary analysis, the missing values were replaced based on the modified loss observation carryforward method for the different versions of discontinuation.",
                    "label": 0
                },
                {
                    "sent": "Following several sensitivity rules and Rule 1 main, one for the analysis as per protocol imputation was done in cases of discontinuation due to toxicity or lack of efficacy.",
                    "label": 1
                },
                {
                    "sent": "No imputation was done in other cases since their northern observed values are considered missing at random.",
                    "label": 0
                },
                {
                    "sent": "Hold 'em gates of Death via score was replaced by several two key sensitivity analysis were provided, incorporating all patients.",
                    "label": 1
                },
                {
                    "sent": "The intention to treat population based on the imputation model for missing values.",
                    "label": 0
                }
            ]
        },
        "clip_20": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "Let's see the patients characteristics and disposition at baseline.",
                    "label": 0
                }
            ]
        },
        "clip_21": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "Baseline practices of the samples in a good pick up the general ILS population and the different treatment arms were balance 133 patients on placebo, 130 on messaging 4.5 one 131 on marketing, 3 point no.",
                    "label": 0
                },
                {
                    "sent": "38% were women, 62% men and male female ratio of 1.684% were normal processors versus 16 fast progressors mean production rate was .7 per month in the intention to treat population .5 per month in the normal progressors BLS functional rating score at baseline was between 37.7 and 39.3 been slightly lower in the massive arms as it was.",
                    "label": 0
                },
                {
                    "sent": "The first vital capacity.",
                    "label": 0
                },
                {
                    "sent": "Main aids was around 55.5.",
                    "label": 0
                },
                {
                    "sent": "Bulbar onset patients were 17% versus 80.",
                    "label": 0
                },
                {
                    "sent": "Three of his spinal onsets, group groups within regions were also balance, being about 64% of the patients from Western Europe and North America.",
                    "label": 0
                },
                {
                    "sent": "Five person from Eastern Europe, 31% from other countries, Argentina.",
                    "label": 0
                }
            ]
        },
        "clip_22": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "The ADT population included 394 patients.",
                    "label": 0
                },
                {
                    "sent": "Of those, 330 normal progressors safety assessment population included patients with at least one drug intake.",
                    "label": 1
                },
                {
                    "sent": "The efficacy assessment population, including patients with at least one post baseline evaluation in three well balanced arms.",
                    "label": 0
                },
                {
                    "sent": "On on all assessments, normal pressures remain about 84% of the total population.",
                    "label": 0
                }
            ]
        },
        "clip_23": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "Cheap.",
                    "label": 0
                },
                {
                    "sent": "Different courts remain well balanced till the end, as similar proportion of patients reached the Week 48 around 60% of the total population of normal and fast progressors 65% of the normal process court.",
                    "label": 0
                }
            ]
        },
        "clip_24": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "The study results were as follow.",
                    "label": 0
                }
            ]
        },
        "clip_25": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "As defined in the protocol, step one analyze the normal process scored almost in 4.5 versus the normal process score on placebo.",
                    "label": 0
                }
            ]
        },
        "clip_26": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Prespecified primary analysis of the trials.",
                    "label": 1
                },
                {
                    "sent": "Main in point, the absolute change in the islets.",
                    "label": 1
                },
                {
                    "sent": "FRS score at 48 weeks of the normal process.",
                    "label": 0
                },
                {
                    "sent": "Court showed that normal producers taking 4.5 milligrams per kilo per day had a least square.",
                    "label": 0
                },
                {
                    "sent": "Mean deterioration of nine point 4.",
                    "label": 1
                },
                {
                    "sent": "Name name .24 points versus 12.63 those normal process on placebo.",
                    "label": 0
                },
                {
                    "sent": "This represents a difference of three point 39 points with a significant value of .015.",
                    "label": 0
                }
            ]
        },
        "clip_27": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "The primary analysis was supported by several key sensitivity analysis based on imputation model.",
                    "label": 0
                },
                {
                    "sent": "On reasons for discontinuation all of these sensitivity analysis resulted, positive as at a significant P value.",
                    "label": 0
                }
            ]
        },
        "clip_28": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "The last two of these analysis included the entire intention to treat population.",
                    "label": 0
                },
                {
                    "sent": "Rule 6 is a single imputation method.",
                    "label": 1
                },
                {
                    "sent": "Copy in increments from similar patients.",
                    "label": 1
                },
                {
                    "sent": "Imputation is done by clustering of similar patience by side of onset by region and treatment group and then using the mean main increment within the group to impute for that value.",
                    "label": 0
                },
                {
                    "sent": "Route 7 is same as Rule 6, but imputation includes a penalty of 50% to those patients who discontinued due to lack of efficacy.",
                    "label": 0
                },
                {
                    "sent": "Both rules showed showed benefit at significant P values.",
                    "label": 0
                },
                {
                    "sent": "She.",
                    "label": 0
                },
                {
                    "sent": "Showed the same benefit at significant P values.",
                    "label": 0
                },
                {
                    "sent": "This analysis followed the European Medicine Agency guidance.",
                    "label": 0
                }
            ]
        },
        "clip_29": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "On a graph.",
                    "label": 0
                },
                {
                    "sent": "Of the LS FRS slopes.",
                    "label": 0
                },
                {
                    "sent": "We can appreciate different progressions rates of both courts.",
                    "label": 0
                },
                {
                    "sent": "Normal patients on massive normal producers.",
                    "label": 0
                },
                {
                    "sent": "Patients on Macedonia 4.5 deteriorated at the rate of .77 per month versus 1.5 those on placebo.",
                    "label": 0
                },
                {
                    "sent": "Do.",
                    "label": 0
                },
                {
                    "sent": "This is 27% reduction of the slope drop above the mostly accepted threshold of 20% of a clinically meaningful benefit.",
                    "label": 0
                }
            ]
        },
        "clip_30": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "I said before the trial enrolled patients with the disease of up to 36 months.",
                    "label": 0
                },
                {
                    "sent": "The poster analysis of the patients with the disease duration of up to 18 an up to 24 months at onset of treatment showed that the treatment effect increase inversely to the richest duration.",
                    "label": 1
                },
                {
                    "sent": "Three points at three point, 39 points of means.",
                    "label": 0
                },
                {
                    "sent": "Difference of Macedonia versus placebo in those with less than 36 months.",
                    "label": 0
                },
                {
                    "sent": "That's deep.",
                    "label": 0
                },
                {
                    "sent": "The trials population the complete trails population.",
                    "label": 1
                },
                {
                    "sent": "Versus 3.8 points.",
                    "label": 0
                },
                {
                    "sent": "If only analyze the patients with up to 20 four months of disease had answered of the triel versus 4.4 points difference.",
                    "label": 0
                },
                {
                    "sent": "If we get patients with the disease up to 18 months at the onset of the trial.",
                    "label": 0
                },
                {
                    "sent": "Most patients at the this is the difference.",
                    "label": 0
                },
                {
                    "sent": "Absurdity why it's moving this.",
                    "label": 0
                },
                {
                    "sent": "OK.",
                    "label": 0
                },
                {
                    "sent": "This was a difference of a 27%.",
                    "label": 0
                },
                {
                    "sent": "Of these two values, there is a difference of a 35% of the two values between placebo.",
                    "label": 0
                },
                {
                    "sent": "An treated patients more space inside the diagnosis.",
                    "label": 0
                },
                {
                    "sent": "When is when the therapy is initiated.",
                    "label": 0
                },
                {
                    "sent": "They usually have less than 18 months of this is so we we should expect that this the sooner the patient is treated after they are gnosis, the more benefit is going to obtain from from the drug.",
                    "label": 0
                }
            ]
        },
        "clip_31": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "The analysis.",
                    "label": 0
                },
                {
                    "sent": "Of the secondary valuable, they BFS and points showed benefit also again, this time to have an endpoint was established as the time that the patient takes to reach 9 points drop in the LS functional rating scale or death.",
                    "label": 0
                },
                {
                    "sent": "Normal producers on Macedonia 4.5 loss 9 points or die at the median of 20 months beds for 16 months.",
                    "label": 0
                },
                {
                    "sent": "Those on placebo.",
                    "label": 0
                },
                {
                    "sent": "With a Wilkinson P value of .0 fifteen.",
                    "label": 0
                },
                {
                    "sent": "This represents a benefit of a 25% read.",
                    "label": 0
                }
            ]
        },
        "clip_32": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "Action time.",
                    "label": 0
                },
                {
                    "sent": "The analysis of these secondary variable that changes in the Alsac 40.",
                    "label": 0
                },
                {
                    "sent": "The quality of life scale showed again a positive result at 48 weeks.",
                    "label": 0
                },
                {
                    "sent": "The patients normal plus normal producers on Macedonia 4.5 deteriorated, 7.75 points less on the scale than those normal process on placebo.",
                    "label": 0
                },
                {
                    "sent": "This represents a 28.5% improvement sustained by a significant significant P value of.",
                    "label": 0
                },
                {
                    "sent": "In 08.",
                    "label": 0
                }
            ]
        },
        "clip_33": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "The analysis of the first secondary endpoint, the change in the first vital capacity of 48 weeks, was also positive defensive means at 48 weeks of 7.5 points and improvement of 22% at the P value of .03.",
                    "label": 0
                }
            ]
        },
        "clip_34": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "The analysis of a fourth secondary variable.",
                    "label": 0
                },
                {
                    "sent": "They combine assessment of functional survival, show their numerical benefit, but did not reach significant level, and so was the analysis of their fifth secondary variable.",
                    "label": 0
                },
                {
                    "sent": "Overall survival and medical benefit without significance, we know.",
                    "label": 0
                },
                {
                    "sent": "The patients that to detect significant difference in overall survival, we need trials with longer duration and large larger sample sizes.",
                    "label": 0
                }
            ]
        },
        "clip_35": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "As a stab Lish, Step 2 analyze the efficacy of the normal process core taking massive net 3.0 MG per.",
                    "label": 0
                }
            ]
        },
        "clip_36": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "Killer one day.",
                    "label": 0
                },
                {
                    "sent": "But the primary analysis, the change in the areas FL score.",
                    "label": 0
                },
                {
                    "sent": "There was a numerical benefit of 273 points, but the P value of .06 was slightly above the significant level of .05 trend.",
                    "label": 0
                },
                {
                    "sent": "This numerical benefit represents her retardation of the rate of progression of a 24% point.",
                    "label": 0
                },
                {
                    "sent": "72 points per month versus .92 per month.",
                    "label": 0
                }
            ]
        },
        "clip_37": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "With a P value of .05.",
                    "label": 0
                },
                {
                    "sent": "The analysis of the Alsac 40 deterioration showed a statistically significant benefit for the normal professors.",
                    "label": 1
                },
                {
                    "sent": "All machine 3.0 with the least square mean of 23.6 points.",
                    "label": 0
                },
                {
                    "sent": "Those on placebo versus 15.6 those on messaging.",
                    "label": 0
                },
                {
                    "sent": "If the quality of life score deteriorated, a significant 34% less.",
                    "label": 1
                }
            ]
        },
        "clip_38": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "However, no significant benefit was observed in the analysis of the secondary endpoints progression free survival force, vital capacity caps, and overall survival.",
                    "label": 0
                }
            ]
        },
        "clip_39": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "This sequence, preestablished step three, and step four, and allies B total population normal plus faster processors.",
                    "label": 0
                }
            ]
        },
        "clip_40": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "No significant benefit was observed in the primary analysis.",
                    "label": 1
                },
                {
                    "sent": "The changing the ILS FRS score of this court.",
                    "label": 0
                },
                {
                    "sent": "Normal producers on massive need 4.5 or all massive need 3.0 no analysis on secondary variables were then done.",
                    "label": 0
                },
                {
                    "sent": "However.",
                    "label": 0
                }
            ]
        },
        "clip_41": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "In a post of analysis, normal fast progressors almost 84.5 with up to 20 four months of this is at entry, no up to 36 as it was in the entire trial.",
                    "label": 0
                },
                {
                    "sent": "Just that group of patients had any statistically significant median progression.",
                    "label": 0
                },
                {
                    "sent": "Free survival of 15 months versus 11 on Windows on placebo.",
                    "label": 0
                },
                {
                    "sent": "This 36% improvement.",
                    "label": 0
                },
                {
                    "sent": "Similar result was obtained in the normal and fast Progressors population or Macedonia 4.5 with up to 18 months of this is at entry.",
                    "label": 0
                },
                {
                    "sent": "These results, as at as those in the previously described postdoc analysis or normal processors, support the impression that they Macedonia treatment seems to be more effective.",
                    "label": 0
                },
                {
                    "sent": "The sooner is initiated.",
                    "label": 0
                }
            ]
        },
        "clip_42": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "Safety profile",
                    "label": 0
                }
            ]
        },
        "clip_43": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "The adverse events profile of Massive was acceptable when compared to placebo.",
                    "label": 0
                },
                {
                    "sent": "Although there is a difference in serious or severe adverse event numbers, the Chi Square P values were not significant at all categories.",
                    "label": 0
                },
                {
                    "sent": "Adverse event leading to death included all adverse events with onset while treated or within 20 days of discontinuation that ended in death.",
                    "label": 1
                },
                {
                    "sent": "None was related to the study treatment.",
                    "label": 0
                },
                {
                    "sent": "Safety profile of Machine if Placerville Shalin system organ class deserves appears acceptable so where severe adverse events were spread across various system organs but in limited numbers here presented those with the frequency equal or higher than 2% in any arm.",
                    "label": 0
                },
                {
                    "sent": "The treatment was in general well tolerated.",
                    "label": 0
                },
                {
                    "sent": "Most common non serious adverse event where skin rashes that mostly resolved in few days spontaneously or by antihistaminic therapy.",
                    "label": 1
                },
                {
                    "sent": "Discontinuing this study drug for a few days or reducing his dose.",
                    "label": 0
                },
                {
                    "sent": "4.7% of patients on messaging is 4.5 had to permanently discontinue the treatment because of this one case of possible Patrick toxicity was reported that resolved after treatment discontinuation and a short lasting.",
                    "label": 0
                },
                {
                    "sent": "Immunosuppressive therapy and two others.",
                    "label": 0
                },
                {
                    "sent": "See.",
                    "label": 0
                }
            ]
        },
        "clip_44": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "And two others with high elevation of ALT and AST and bilirubin were suspicious of and resolve without treatment after discontinuation.",
                    "label": 0
                },
                {
                    "sent": "My significant operationally increase levels of Ald NST battery may also be a path to toxic, and their combination may contribute to that specific adverse event in genetically predisposed patients to be studied.",
                    "label": 0
                }
            ]
        },
        "clip_45": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "On summary",
                    "label": 0
                }
            ]
        },
        "clip_46": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Madden, if at the doors of 4.5 milligrams but below a day or night twice a day, oral administration demonstrated a significant therapeutic benefit in patients with the production rate on the LS FRS at baseline of less than 1.1 points per month.",
                    "label": 1
                },
                {
                    "sent": "Those patients experiences lowering the functional decoration of a 27%.",
                    "label": 0
                },
                {
                    "sent": "Delate this is progression of 25% quality of life at 28% higher and adelaid loss of respiratory function of a 22%.",
                    "label": 1
                },
                {
                    "sent": "Safety susceptible by the Patrick function controls are recommended.",
                    "label": 1
                },
                {
                    "sent": "The effects the effect of the massive seems to be dose dependent patients on Mass Effect 3.0 experience a benefit, but fell slightly short on significant in the functional deterioration, though will treats significance on quality of life.",
                    "label": 0
                },
                {
                    "sent": "The benefit is not only dependent.",
                    "label": 0
                },
                {
                    "sent": "On a dose of the city, but also in the time of the disease when the treatment is initiated, the shorter duration, the more effective the treatment.",
                    "label": 0
                },
                {
                    "sent": "All patients normal and fast.",
                    "label": 0
                },
                {
                    "sent": "Progressors or Macedonia 4.5 had a progression.",
                    "label": 0
                },
                {
                    "sent": "Free survival 35% higher than those on placebo.",
                    "label": 0
                },
                {
                    "sent": "When therapy was initiated less.",
                    "label": 0
                },
                {
                    "sent": "Less than 40.",
                    "label": 0
                },
                {
                    "sent": "But when did Washington state there the last less than 20 four months of this is?",
                    "label": 1
                },
                {
                    "sent": "As they decide this of this trial seems to demonstrate.",
                    "label": 0
                },
                {
                    "sent": "Much did, it provides a new and significant therapeutic option for around an 85% of the LS population, probably more so if the treatment is initiated early in the disease.",
                    "label": 0
                },
                {
                    "sent": "It compared favorably with another recently approved therapy.",
                    "label": 0
                },
                {
                    "sent": "Thank you very much for your attention.",
                    "label": 0
                }
            ]
        },
        "clip_47": {
            "is_summarization_sample": false,
            "summarization_data": []
        }
    }
}